ABOUT US

Theryte Ltd was founded as a Liverpool based, venture capital backed biotechnology spin-out from the University of Liverpool in June 1998, to develop new cancer diagnostics and delivery systems.  The Company has been built on the pioneering work of Professor Hilmar Warenius, who has developed a radically new, breakthrough understanding of cancer, and how new therapeutic agents can be developed to treat established cancers.  In addition to directing research and development, Professor Warenius brings to the company his many years experience as a clinical oncologist.

The Company has recently refocused its activities, securing IP assets and accelerating drug discovery efforts.  Value will be created through the assembly of a group of managers and scientific technologists to commercialise the Company’s technology and products.  A new strategic plan has been approved for major growth to create new drugs and complete serial licensing deals with large biotechnology and pharmaceutical companies.

A chemical development program has yielded the Company’s lead candidate, THR-53, which kills cancer cells but does not affect normal cells.  Death of the cancer cells takes place over a period of weeks after ‘programming’ through initial treatment over just one or two days.

The Company has raised over £2.0 million pounds so far from grants and private investors, through a number of small rounds, the most recent of which was completed in January 2007, with support from Esperante BV , Fenwall Investments and the Founder.

The Directors are:

Mr Peter Dohrn (Chairman), Prof. Hilmar Warenius (Chief Medical Officer & Director of R&D), Mr Dean Slagel (nominated by Esperante), Mr Andrew Douglas (nominated by Fenwall).